CD33CART allogeneic

Biologic

CCenter for International Blood and Marrow Transplant Research

CD33CART allogeneic is one of 32 biologic programs targeting Acute Myeloid Leukemia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

5 2

Dalalone

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 3

1 3

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Lenograstim

Sanofi

Phase 3

1 5

Caspofungin Acetate

Merck & Co.

Phase 3

1 6

Experimental

Biogen

Phase 3

1 7

AG-120

Institut de Recherches Internationales Servier

Phase 3

4 8

Valspodar

EEastern Cooperative Oncology Group

Phase 3

3 9

Salvage Chemotherapy

Daiichi Sankyo

Phase 3

1 10

Homoharringtonine

Ascentage Pharma Group Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2039

Phase 1/2Active, not recruiting

Acute Myeloid Leukemia

NCT03971799

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

Active, not recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 1/2·NCT03971799·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD33CART allogeneic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD33CART allogeneic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD33CART allogeneic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Center for International Blood and Marrow Transplant Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: CCenter for International Blood and Marrow Transplant Research

CD33CART allogeneic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2039

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News